When leadership changes at the FDA, as with Vinay Prasad succeeding Peter Marks, a core tension emerges. The new head isn't obligated to follow prior agreements, but abruptly shifting regulatory expectations for companies mid-development creates industry whiplash and erodes trust in the agency's consistency.

Disagreements between FDA review teams and senior leadership, like CBER head Vinay Prasad, create contradictory guidance for drug sponsors. Companies follow the review team's advice, only to be overruled by leadership, leading to wasted resources, delayed approvals, and significant frustration.

Despite the FDA leadership co-authoring an editorial supporting single-trial approvals, the industry is skeptical. The agency's recent inconsistent actions mean no executive or investor can confidently build a development strategy or financial model based on this policy, rendering the announcement largely ineffective.

Unicure's setback with its Huntington's gene therapy demonstrates a new political risk at the FDA. A prior agreement on a trial's design can be overturned by new leadership, especially if the data is not overwhelmingly definitive. This makes past regulatory alignment a less reliable indicator of future approval.

Unpredictable changes in FDA review processes are more destructive to biotech investment than consistently high approval standards. Investors can adapt to a stringent but stable regulatory bar, but constant changes undermine the multi-year planning and capital commitment required for drug development, causing investors to flee.

Richard Pazdur's immediate goal as the new CDER director is to restore stability and integrity at the FDA. His initial focus will be on rebuilding the team by recruiting, retaining, and empowering staff—deferring major policy shifts like accelerated approval reform until the agency's morale and operational capacity are restored.

FDA CBER Director Vinay Prasad is reportedly overriding staff recommendations not just in his own center (vaccines), but also in CEDAR (drugs), as seen in the Disc Medicine case. This consolidation of decision-making power in one individual is making FDA approvals far more unpredictable for drug developers.

Following the exit of controversial CBER director Vinay Prasad, the FDA approved several drugs that might have struggled under his tenure. This suggests a potential shift towards more regulatory flexibility, possibly influenced by political pressure ahead of midterm elections, creating opportunities for sponsors with controversial applications.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.